Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Ardelyx, Inc.

Arthex Biotech is involved in modulating microRNAs and developing innovative medicines. The company is focused on investigating anti-miRs to treat diseases with unmet medical needs.

Arthex Biotech

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Avidity Biosciences, Inc.

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Nick Lydon

Chris Varma

Brian Druker

Alexis Borisy

Blueprint Medicines Corporation

Ardelyx focuses on developing first-in-class medicines for patients with unmet medical needs, particularly in the areas of chronic kidney disease and irritable bowel syndrome.

Metric
Company Name	Ardelyx, Inc.	Arthex Biotech	Avidity Biosciences, Inc.	Blueprint Medicines Corporation
Symbol	ARDX		RNA	BPMC
MSH ID	COM:ARDELYX	COM:ARTHEXBIOTECH	COM:AVIDITYBIOSCIENCES	COM:BLUEPRINTMEDICINES
Market	STOCKS	PRIVATE	STOCKS	STOCKS
Sector	Healthcare	Healthcare & Health Services	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	US	ES	US	US
Stage	Debt
Employee Count	267		253	645
Website	ardelyx.com	arthexbiotech.com	aviditybiosciences.com	blueprintmedicines.com
LinkedIn
Founders

Metric
Market Cap	1.30B	4.07B	7.26B
Enterprise Value
Monthly Web Traffic	33.50K
Web Traffic Growth	2.80
Valuation
Raised Capital	20M

Metric
Revenue	124.46M	9.56M	249.38M
Revenue (LTM)
Revenue (NTM)
Gross Profit	106.66M	7.46M	224.92M
EBITDA	-55.35M	-233.50M	-474.61M
Operating Income	-63.28M	-235.60M	-486.28M
Net Income	-66.07M	-212.22M	-506.98M
EPS	-0.30	-2.91	-8.37
Diluted EPS	-0.30	-2.91	-8.37
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.86	0.76	0.96
Operating Profit Margin	-0.28	-23.48	-0.98
EBITDA Margin	-0.44	-24.42	-1.90
Net Profit Margin	-0.31	-21.04	-0.57
Return on Equity	-0.40	-0.33	-0.85
Return on Assets	-0.19	-0.19	-0.17
Return on Capital Employed	-0.21	-0.23	-0.37

COM:ARDELYX

Ardelyx

Last Close

5.12

22/11 21:00

Market Cap

1.30B

Beta: -

Volume Today

3.79M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-74.58	-4.46	-8.39
P/B Ratio	10.37	1.68	22.98
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	14.47	557.48	26.58
EV Multiple	-20.25	-8.85	-9.68

Metric
Days Sales Outstanding	117.61		69.65
Days Payables Outstanding	185.33		170.58
Days Inventory Outstanding	264.91		952.36
Operating Cycle	329.52	72.73	1.03K
Cash Conversion Cycle	100.07		878.40
Asset Turnover	0.61	0.02	0.30

Metric
Operating Cash Flow	-89.72M	-119.06M	-436.85M
Free Cash Flow	-90.06M	-123.29M	-452.91M
Cash Flow to Debt	-0.77	-12.09	-0.50
Operating Cash Flow/Sales	-0.41	-12.45	-0.92
Free Cash Flow Yield	-0.03	-0.21	-0.11

Metric
Cash & Equivalents	21.47M	185.08M	71.29M
Accounts Receivable	-14.30M		-7.65M
Inventory	12.45M		21.22M
Goodwill
Debt to Capitalization	0.41	0.02	0.84
Debt to Assets	0.12	0.02	0.11
Current Ratio	5.54	11.40	4.09
Quick Ratio	4.36	15.97	3.65

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.09	3.52	0.44
R&D to Revenue	0.26	18.13	2.08
SG&A to Revenue	0.15	4.78	0.51